T1	Participants 56 88	extensive small-cell lung cancer
T2	Participants 287 378	previously untreated patients with extensive-stage small-cell carcinoma of the lung (SCLC).
T3	Participants 400 531	Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50 and adequate renal function and bone marrow reserve
T4	Participants 980 992	171 patients
T5	Participants 1804 1833	patients with extensive SCLC.
